Skip to main content
SpringerLink
Log in
Book cover

PET/CT in Infection and Inflammation pp 29–41Cite as

PET/CT in Assessment of Sarcoidosis

  • Chapter
  • First Online:

  • 637 Accesses

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

Sarcoidosis is a multi-systemic disease of unknown aetiology with a unique set of diagnostic and management related challenges. PET/CT has been studied extensively for assessing the sites of inflammatory activity and extent of disease. 18FDG PET/CT imaging is a non-invasive tool to assess disease activity, localize occult sites, increases the yield of biopsy, helps in optimizing treatment and detection of relapse. As FDG accumulation is non-specific to the disease process, PET CT can only serve to give complimentary information. With recent availability of many new PET tracers, it may be possible to individualize and optimize treatment; however, larger prospective trials are required to establish their utility. The role of newer technologies like PET/MR and newer tracers (eg. Somatostatin receptor agonists) are exploratory at this time point.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.

    Google Scholar 

  2. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:1537–43.

    Article  PubMed  Google Scholar 

  3. Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011;55:66–71.

    PubMed  CAS  Google Scholar 

  4. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571–6.

    PubMed  Google Scholar 

  5. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–9.

    PubMed  CAS  Google Scholar 

  6. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.

    Article  PubMed  Google Scholar 

  7. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18F-FDGPET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53:1543–9.

    Article  PubMed  Google Scholar 

  8. Keijsers RG, Verzijlbergen FJ, Oyen WJ, van den Bosch JM, Ruven HJ, van Velzen-Blad H, Grutters JC. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging. 2009;36(7):1131–7.

    Article  CAS  PubMed  Google Scholar 

  9. Dalma VA, van hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003;285:E344–53.

    Article  Google Scholar 

  10. ten Bokum AM, Hofland LJ, de Jong G, et al. Immunohistochemical localization of somatostatin receptor in sst2A in sarcoid granuloma. Eur J Clin Investig. 1999;29:630–6.

    Article  Google Scholar 

  11. Soydal C, Kucuk O, Ozkan E, Kumbasar O, Kir M. Ga-68 DOTATATE accumulation in sarcoidosis. Int J Nucl Medi Res. 2015;2:1–4.

    Article  Google Scholar 

  12. Nobashi T, Nakamoto Y, Kubo T, Ishimori T, Handa T, Tanizawa K, Sano K, Mishima M, Togashi K. The utility of PET/CT with (68)Ga-DOTATOC in sarcoidosis: comparison with (67)Ga-scintigraphy. Ann Nucl Med. 2016;30(8):544–52.

    Article  CAS  PubMed  Google Scholar 

  13. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86.

    PubMed  CAS  Google Scholar 

  14. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med. 2010;31:409–18.

    Article  PubMed  Google Scholar 

  15. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573–81.

    Article  CAS  PubMed  Google Scholar 

  16. Drent M, De Vries J, Lenters M, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol. 2003;13:2462–71.

    Article  PubMed  Google Scholar 

  17. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol. 2000;174:1751–7.

    Article  CAS  PubMed  Google Scholar 

  18. Mostard RL, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Vöö S, Drent M. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med. 2013;107(3):439–47.

    Article  PubMed  Google Scholar 

  19. Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, Hughes JM. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21(4):297–305.

    Article  CAS  PubMed  Google Scholar 

  20. Keijsers RG, Verzijlbergen EJ, van den Bosch JM, Zanen P, van de Garde EM, Oyen WJ, Grutters JC. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):123–9.

    PubMed  CAS  Google Scholar 

  21. Basu S, Yadav M, Joshi JM, Desai D, Moghe S. Active pre-treatment purepulmonary parenchymal sarcoidosis with raised serum angiotensin converting enzyme level: characteristics on PET with glucose metabolism and cell proliferation tracers and HRCT. Eur J Nucl Med Mol Imaging. 2011;38(8):1584–5.

    Article  PubMed  Google Scholar 

  22. Rayamajhi SJ, Mittal BR, Maturu VN, Agarwal R, Bal A, Dey P, Shukla J, Gupta D. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Ann Nucl Med. 2016;30(3):207–16.

    Article  CAS  PubMed  Google Scholar 

  23. Koo HJ, Kim MY, Shin SY, Shin S, Kim SS, Lee SW, Choi CM. Evaluation of mediastinal lymph nodes in sarcoidosis, sarcoid reaction, and malignant lymph nodes using CT and FDG-PET/CT. Medicine (Baltimore). 2015;94(27):e1095.

    Article  CAS  Google Scholar 

  24. Iwai K, Tachibana Y, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–6.

    PubMed  CAS  Google Scholar 

  25. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119(2):167–72.

    PubMed  CAS  Google Scholar 

  26. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11.

    Article  PubMed  Google Scholar 

  27. Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F- fluorodeoxyglucosepositron emission tomography: an autopsy case. Circulation. 2010;122:535–6.

    Article  PubMed  Google Scholar 

  28. Hiraga H, Hiroe M, Iwai K, et al. Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases. Tokyo: The Japanese Ministry of Health and Welfare; 1993. p. 23–4. in Japanese.

    Google Scholar 

  29. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007;27:89–102.

    Google Scholar 

  30. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med. 2014;55:99–106.

    Article  PubMed  Google Scholar 

  31. Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.

    Article  CAS  PubMed  Google Scholar 

  33. Birnie D. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23.

    Article  PubMed  Google Scholar 

  34. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801–10.

    Article  PubMed  Google Scholar 

  35. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926–36.

    Article  PubMed  Google Scholar 

  36. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151–6.

    Article  PubMed  Google Scholar 

  37. Lum DP, Wandell S, Ko J, Coel MN. Reduction of myocardial 2-deoxy-2-[18F] fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol. 2002;4:232–7.

    Article  PubMed  Google Scholar 

  38. Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand. 1988;724:1–56.

    Article  CAS  Google Scholar 

  39. Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2015;23:244–52.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A doseresponse study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol. 1979;7:531–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, Ito N, Ohira H, Ikedo D, Tamaki N, Nishimura M. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26(15):1538–43.

    Article  PubMed  Google Scholar 

  42. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, Baba K, Ishibashi M, Hayabuchi N, Narula J, Imaizumi T. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3(12):1219–28.

    Article  PubMed  Google Scholar 

  43. Norikane T, Yamamoto Y, Maeda Y, Noma T, Dobashi H, Nishiyama Y. Comparative evaluation of (18)F-FLT and (18)F-FDG for detecting cardiac and extra-cardiac thoracic involvement in patients with newly diagnosed sarcoidosis. EJNMMI Res. 2017;7(1):69.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, Miura M, Sakaue S, Tamaki N, Nishimura M. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35(5):933–41.

    Article  PubMed  Google Scholar 

  45. Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P. A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res. 2016;6(1):52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Lapa C, Reiter T, Kircher M, Schirbel A, Werner RA, Pelzer T, Pizarro C, Skowasch D, Thomas L, Schlesinger-Irsch U, Thomas D, Bundschuh RA, Bauer WR, Gärtner FC. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget. 2016;7(47):77807–14.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Grozdic Milojevic I, Sobic-Saranovic D, Videnovic-Ivanov J, Saranovic D, Odalovic S, Artiko V. FDG PET/CT in bone sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(1):66–74.

    PubMed  Google Scholar 

  48. Soussan M, Augier A, Brillet PY, Weinmann P, Valeyre D. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med. 2014;39(2):e146–59.

    PubMed  Google Scholar 

  49. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32(1):47–59.

    Article  PubMed  Google Scholar 

  50. Aide N, Allouache D, Ollivier Y, de Raucourt S, Switsers O, Bardet S. Early 2′-deoxy-2′-[18F]fluoro-D-glucose PET metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like lesions. Mol Imaging Biol. 2009;11(4):224–8.

    Article  PubMed  Google Scholar 

  51. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):143–9.

    PubMed  CAS  Google Scholar 

  52. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D, Djuric-Stefanovic A, Masulovic D, Odalovic S, Ilic-Dudvarski A, Popevic S, Pavlovic S, Obradovic V. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53(10):1543–9.

    Article  PubMed  Google Scholar 

  53. Vorselaars AD, Verwoerd A, van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–9.

    Article  CAS  PubMed  Google Scholar 

  54. Maturu VN, Rayamajhi SJ, Agarwal R, Aggarwal AN, Gupta D, Mittal BR. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(4):372–80.

    PubMed  Google Scholar 

  55. Tirpude S, Basu S, Joshi JM. FDG-PET scan in management of pulmonary sarcoidosis. J Assoc Physicians India. 2013;61(4):276.

    PubMed  Google Scholar 

  56. Basu S, Asopa RV, Baghel NS. Early documentation of therapeutic response at 6 weeks following corticosteroid therapy in extensive sarcoidosis: promise of FDG-PET. Clin Nucl Med. 2009;34(10):689–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, India

    Ashwini Kalshetty, Pradeep Thapa & Sandip Basu

  2. Homi Bhabha National Institute, Mumbai, India

    Ashwini Kalshetty & Sandip Basu

Authors
  1. Ashwini Kalshetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pradeep Thapa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandip Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom

    Thomas Wagner

  2. Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, India

    Sandip Basu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kalshetty, A., Thapa, P., Basu, S. (2018). PET/CT in Assessment of Sarcoidosis. In: Wagner, T., Basu, S. (eds) PET/CT in Infection and Inflammation . Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-90412-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90412-2_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90411-5

  • Online ISBN: 978-3-319-90412-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation